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Summary
Resting autoreactive T cells are present in the circulation ofnormal individuals without patho-
logic consequences. In autoimmune animal models, stimulation of these self-reactive T cells in
the presence of costimulatory molecules B7-1 results in T cell-mediated autoimmune disease,
whereas B7-2 stimulation generates regulatory autoreactive T cells that abrogate disease sever-
ity. Thus, reactivation in the brain of myelin-autoreactive T cells by antigen with costimula-
tory molecules may be a critical event in the pathophysiology of multiple sclerosis (MS), a pu-
tative autoimmune disease of central nervous system (CNS) myelin. We investigated the
expression of cytokines and costimulatory molecules in a panel of 41 histologically character-
ized CNS specimens from 15 MS and 10 control cases using semiquantitative reverse tran-
scriptase-polymerase chain reaction and immunocytochemistry. In four cases, vascular CNS in-
farcts with inflammation were compared with MS plaques from the same brain. We observed
increased expression ofB7-1 and interleukin (IL) 12p40 in acute MS plaques, particularly from
early disease cases but not in inflammatory infarcts. B7-1 staining was localized predominantly
to the lymphocytes in perivenular inflammatory cuffs but not the parenchyma. In contrast,
B7-2 was expressed predominantly on macrophages both in MS lesions ofvaried time duration
and in inflammatory infarcts. These findings indicate that an early event in the initiation ofMS
involves upregulation o£ B7-1 and IL-12, resulting in conditions that maximally stimulate
T cell activation and induction of T helper 1-type immune responses.
A
utoimmune disease is presumably mediated by acti-
vated, autoantigen-reactive T cells (1-8) . Two distinct
signals are required to induce differentiation of naive to ac-
tivated, effector T cells: an antigen-specific signal mediated
through the T cell receptor, and a second non-antigen-
specific "costimulatory" signal (9, 10) . Interactions be-
tween CD28 and its counterreceptors, B7-1 (CD80) and
B7-2 (CD86), are important T cell-costimulatory signals
(11, 12) . Essentially all CD4+ and most CD8+ T cells ex-
press CD28 constitutively, and CD28-deficient T cells
show a markedly reduced response to antigen stimulation
(13) . A second ligand for B7 is CTLA-4, which is ex-
pressed on T cells after activation (14) and also may regu-
late T cell function (15) . The B7 molecules regulate IL-2
secretion and costimulate T cell proliferation (16-18) .
Blocking of the B7-CD28 pathway in vitro results in T cell
anergy (19-21) whereas in vivo blocking of the B7-CD28
pathway results in immunosuppression (22-24) .
Aberrant expression of B7-costimulatory molecules is
important in experimental autoimmune diabetes. Double-
transgenic mice with T cell receptors recognizing a viral
antigen expressed on pancreatic islet cells do not develop
diabetes. Triple-transgenic mice that additionally expressed
B7-1 on pancreatic islet cells, however, developed massive
tissue destruction and diabetes (25) . Moreover, double trans-
genic mice expressing both MHC class II and B7-1 mole-
cules on pancreatic islet cells developed diabetes (26) . These
findings suggest that autoreactive T cells, which are a part
of the normal T cell repertoire, are usually maintained tol-
erant to peripheral self-antigens because ofthe regulated ab-
sence of B7-costimulatory molecules on parenchymml cells.
Multiple sclerosis (MS)' is a chronic inflammatory dis-
ease characterized by lymphocyte infiltration and demyeli-
nation in the central nervous system (CNS) (27) . Experi-
IAbbreviations used in this paper: CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; MS, multiple sclerosis; RT-PCR,
reverse transcriptase PCR; SSPE, subacute sclerosing panencephalitis.
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autoimmune CNS disease, shows pathologic similarities to
MS (28). EAE is mediated by CD4+ T cells secreting the
cytokknns IL-2, IFN-'Y, TNF-ot, and lymphotoxin, which
are defined as Thl cells, whereas recovery is associated with
the secretion of IL-4, IL-10, and TGF-(31, known as Th2
cells (29, 30). The type of effector T cell is determined by
the cytokine microenvironment at the time of primary
stimulation and by signals induced by costimulatory mole-
cules (31). IL-12 and B7-1 costimulation is important for
differentiation into Thl cells, whereas IL-4 and perhaps
B7-2 induce a Th2 response (32-40). The IL-12p40 sub-
unit is transcriptionally regulated, and expression correlates
with secretion of the active cytokine. Previous studies have
suggested a pathogenic role for IFN-y and TNF-ot in pa-
tients with MS and other autoimmune diseases (41-47).
A critical link between human autoimmune diseases and
their experimental counterparts involves understanding events
associated with the activation and differentiation of autore-
active T cells. Here, we investigated expression of theB7-1-
and B7-2-costimulatory molecules in relationship to cy-
tokine mRNA expression using a sensitive semiquantitative
PCR method and immunohistochemistry. 41 plaques from
15 MS brains, including difficult-to-obtain tissue from two
subjects with clinical MS for <2 yr duration, were com-
pared with tissue from inflammatory infarcts, chronic viral-
induced inflammatory lesions, and normal control brain.
We observed increased expression of B7-1 by reverse tran-
scriptase (RT)-PCR and immunohistology and IL-12p40
by RT-PCR in acute MS plaques but not in either inflam-
matory infarcts or normal control brains. In contrast, B7-2
was expressed predominantly on macrophages both in MS
lesions and in inflammatory infarcts. These data indicate
that an early event in the initiation of effector cells in MS
involves upregulation of B7-1 and IL-12, resulting in con-
ditions that promote T cell clonal expansion and IFN-y se-
cretion with the breakdown of tolerance.
Materials and Methods
Patients.
￿
41 brain tissue specimens were included in this study.
These samples were obtained at autopsy from 15 clinically and
neuropathologically definite cases of MS and 10 control cases, 8
without neurological disease, 1 with a 2-yr history of subacute
sclerosis panencephalitis, and 1 with a stroke (48). Brain speci-
mens were also obtained in 4 cases from areas ofinfarctin patients
who had MS and died from a stroke. The median age of patients
was 50 yr (range 20-76 yr). Duration of disease was 1-50 yr, in-
cluding two patients who had very short disease durations of 1
and 2 yr, respectively (Table 1). Tissue sections were selected
from areas of either plaques or tissue damage on the basis of gross
examination of the CNS. Foreach subject, alltissue blocks avail-
able were included in the study.
lmmunohistology.
￿
Histology was performed as previously re-
ported (49). Immunohistology was performed to confirm the
RT-PCR results on all frozen blocks that contained tissue that
could be investigated, and all of these results are reported. Ace-
tone-fixed (4°C, 10 min) sections on gelatin-coated slides were
incubated with mouse mAbs directed against CD68 (EBM/11),
CD4, CD22 (Dako, High Wycombe, UK), IL-12 (Genetics In-
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stitute, Cambridge, MA), B7-1 (PharMingen, San Diego, CA), and
B7-2 (PharMingen). Sections were immunoperoxidase stained us-
ing a biotinylated anti-mouse IgG antibody and an avidin-biotin
complex (Vector Laboratories, Inc., Burlingame, CA) as previ-
ously reported (49). All pathology was reviewed by two indepen-
dent observers masked for both the tissue diagnosis and PCR re-
sults. Scoring of pathology is presented in the table legends.
RNA andcDNA Preparation.
￿
Total cellular RNA and cDNA
was extracted and prepared as described previously (49). 5-10 wl
was used for each PCR reaction.
Standardization and PCR Amplification.
￿
Each 25-p,l PCR con-
tained 0.5 wg offorward and 0.5 N.g of reverse primers, 1.2 U of
Taq polymerise, 0.08 p.l of ["P]dCTP, and 10 VI of a mix of
dNTPs and Taq buffer, which was prepared as a master mix for
each set of samplesto ensure the same reaction conditions in each
sample. To avoidintraexperimentalvariation, samples were tested
at the same time with the same PCR mix for each cytokine.
Thermal cycling was performed at 94°C for 1 min, 55°C or 60°C
for 1 min, and 72°C for 1.5 min for 28-35 cycles. Primer se-
quences were derived from the Gen Bank using the OLIGO 4.0
computer program (National Biosciences, Inc., Home], MN).
Primers were made by Oligos, Etc. (Wilsonville, OR). The
primer sequences are shown in Table 2. To ensure linearity of the
PCR and allow comparison of the efficiency of different primer
combinations, an external standard curve for each cytokine was
generated using a dilution series of standard DNA. This PCR
standard was obtained by purification of amplified PCR product
over a minicolumn (Wizardminipreps; Promega Corp., Madison,
WI) and concentration was determined by OD 260 nm reading.
Samples were normalized for their cDNA concentration by com-
parison of [3-actin mRNA levels. Radioactive PCR products were
separatedon 5% polyacrylamide gels andanalyzed on a phosphor-
imager (Betascope 603 Blot Analyzer; Betagen, Waltham, MA).
Radioactivity in each band was counted, and results were ex-
pressed as relative units calculated as cpm cytokine/cpm actin
X 100. mRNA expression is listed as relative units to normalize
for [3-actin concentration, and tissue sections were considered
positive for mRNA expression if the relative units were greater
than twice the standard deviation ofthe average value from non-
inflammatory control brains. Statistical comparisons among the
groups forB7 and IL-12 expression were performed using a two-
tailed Fisher's exact test. Comparison ofages between the groups
was performedusinga two-tailed Mann-Whitney test, as indicated.
ForIL-12p40 mRNA measurement expression, we used acom-
petitive PCR method. We constructed a competitor DNA frag-
ment (MIMIC) that had the same primer annealing sites and am-
plification kinetics as the cDNA, followingthe method described
by Siebert and Larrick (50). The PCR products from the MIMIC
and target differed by length to allow separation by gel electro-
phoresis. Known molar quantities of the competitor were spiked
into a series of PCR reactions. The cDNA concentration of the
sample was determined by comparing the relative intensity o£PCR
product bands from competitor and target cDNA. For the PCR
analysis all samples were coded, and thepathology of the samples
was not known at the time ofthe experiments.
Results
IL-12p40, B7-1, and B7-2 mRNA expressions were ex-
amined in a panel of histologically characterized tissue
specimens from MS patients and normal control subjects.
mRNA expression is listed as relative units normalized toTable 1.
￿
MS Patients and Normal Controls
*Histology cell
￿
Death to
ARDS, adult respiratory distress syndrome; NA, notapplicable.
*See Table3 legend forscoring methods.
1987
￿
Windhagen et al.
Pathologic
diagnosis
Control cases
infiltration/
oil-red O
Tissue
location Age
Disease
duration
yr
Sex
Cause of
death
Kurtzke
scale
freezing
time
h
1 1/0 Parietal 60 - M Pneumonia NA 45
2 0/0 Parietal 42 - M Cardiac arrest NA 21
3 0/0 Cervical cord 20 - M Asthma NA 33
4 0/0 Cerebellum 24 - M Cardiac arrest NA 27
5 1/0 Parietal 43 - M Pneumonia NA 37
6 2/0 Temporal cortex 65 - F Pneumonia NA 30
7 0/0 Periventricular 43 - M Renal failure NA 33
8 1/0 Parietal 40 - F Aortic rupture NA 42
SSPE 9 5/3 Parietal cortex 11 2 F SSPE NA -
Infarct 10 0/2 Occipital 52 - M Cardiac arrest NA 20
MS 1 1/1 Frontal cortex 53 22 M Sepsis 9 56
Infarct-MS 2 0/0 Occipital pole 41 17 F Pneumonia 9 52
MS 2.1 5/0 Occipital
MS 2.2 5/0 Temporal
MS 3 5/0 Cervical cord 50 15 M ARDS 6 29
MS4 1/0 Parietal 62 14 M Cardiac arrest 9 7
MS 5.1 2/1 Occipital 37 10 F Pneumonia 9 24
MS 5.2 2/1 Parietal
MS 6.1 1/3 Cervical cord 36 10 F MS 9 33
MS 6.2 1/3 Cervical cord
MS 7.1 1/1 Pons 52 9 M Sepsis 9 29
MS 7.2 3/3 Pons
MS 7.3 3/3 Pons
MS 8.1 3/5 Parietal 29 7 F Pneumonia 8 14
MS 8.2 2/4 Frontal pole 29 7 F
MS 9.1 3/5 Cervical cord 26 3 M Pneumonia 9 18
MS 9.2 3/5 Periventricular
MS 9.3 2/4 Pons
MS 10 3/5 Cerebellum 22 2 F Brain stem plaque 9 11
MS 11 .1 5/5 Lumbar cord 35 1 M Asphyxia 4 28
MS 11 .2 4/2 Thoracic cord
MS 11 .3 1/1 Corpus callosum
Normal-MS11 2/0 Periventricular
MS 12.1 4/3 Lumbar cord 29 8 F Pneumonia 9 11
MS 12.2 5/4 Occipital 29
MS 13 .1 3/1 Frontal 71 50 F Stroke 8 42
Infarct-MS 13 1/5 Cerebellum
MS 14.1 0/0 Cervical cord 74 16 F Stroke/pulmonary 8 35
embolus
Infarct-MS 14 1/0 Occipital
MS 15 .1 1/0 Lumbar cord 76 41 M Stroke 8 28
Infarct-MS 2/4 ThalamusTable 2 .
￿
Sequences ofIL-12, B7, and Actin Primers Usedfor PCR
Length of
￿
Annealing
Cytokine
￿
PCR Product
￿
temperature
(3-actin concentration. Tissue sections were considered
positive for mRNA expression if the relative units were
greater than twice the standard deviation of the average
value from noninflammatory control brains. These results
are shown in Fig. 1, and representative autoradiographs af-
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ControlsMS Plaques
ter PCP, amplification are shown in Fig. 2. Increased B7-1
expression was observed in 8 of 15 MS cases and in 0 of 9
of the nonviral inflammatory control brains (P <0.009) .
Although none of the inflammatory stroke lesions ex-
pressed B7-1, tissue from a subject with a 2-yr history of
B7-1
B7-2
IL-12p40
-
_
i
Figure 1. mRNA expression of
IL-12p40, B7-1 CD80 and
~ ecmens. DBResultslare shownaas
I`~`~'i`~`r~(~~~~~~~~~y~~
￿
4E
￿
relative units calculated as cpnt
cytokine/cpm actin X 700. The
mean relative index ± 2 SD was
0
￿
calculated for the noninflamma-
tory disease control cases, and is
designated by the stippled line
for B7-1, B7-2, and IL-2. Values
>2 $D over the mean were con-
sidered positive and analyzed by
a Fisher's exact test. (a) Solid bars
represent patients with MS and
cross-hatched bars represent con-
trol brain specimens. In cases ex-
pressing IL-12p40, the average
disease duration was 6.2 ± 2.6
(SE) yr, whereas in the brains
with no IL-12 expression, the
average disease duration was 19.4
tailed Mann-Whitney test) . In-
creased B7-1 expre$sion was ob-
served in 8 of 15 MS cases and in
0 of 9 of the nonviral inflanmta-
tory control brains (P <0.0()9,
two-tailed Fisher's exact test) .
None ofthe inflammatory stroke
lesions expressed B7-l . Tissue
from a SSYE case expressed lev-
MS Plaques and Infarct
￿
els of B7-1 comparable to pa-
tients with MS. 9 of 15 MS cases
and 1 of9 nonviral inflammatory control brains expressed increased levels ofB7-2 mRNA (P <(),03). The frequency of plaque samples with cell infiltra-
tions >3 correlated with positive mRNA expression ofeither B7-1, B7-2 (P <0.005, Fisher's exact test), or IL-12 (P <0.04). (b) Direct comparison of
brain specimens from MS patients with strokes. Solid bars represent MS inflammatory plaques and cross-hatched bars represent stroke lesions front the
same brain. There was little perivascular cell infiltration, whereas significant infiltrations of lipid-laden macrophages were observed in the infarcts (see Fig.
4, c and d).
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(3-Actin
by
406 60°C Forward
Reverse
AAC
GGT
CCC AAG GCC
CAT CAC CTG
AAC
GCC
CGC GAG AAG
GTC AGG CAG
ATG ACC
CTC GTA
IL-12p40 609 60°C Forward ATT CAg TgT CAA AAg CAg CAg Agg
Reverse Tgg gTC TAT TCC gTT gTg TC
IL-12p35 296 60°C Forward CCT CAg TTT ggC CAg AAA CC
Reverse ggT CTT TCT ggA ggC CAg gC
B7-1 389 60°C Forward AAC TCg CAT CTA CTg gCA AAA ggA gAA
Reverse AgA AAA Tgg TgC TgA CTA TgA TgT CTg
137-2 409 60°C Forward TgA TTC ggA CAg TTg gAC CCT gAG AC
Reverse gTA TCA ATg TAT CAT CCA TCA CAA AAA gCCCsubacute sclerosing panencephalitis (SSPE), a chronic CNS
infection by defective measles virus, expressed levels o£B7-1
comparable to patients with MS . Similarly, 9 of 15 MS
cases and 1 of 9 nonviral inflammatory control brains ex-
pressed increased levels of B7-2mRNA (P <0.03) . Direct
assessment ofB7-1 expression showed 4 X 10-3 attomoles/
p1 for B7-1 and 2 X 10- '- attomoles/p,l for B7-2 expres-
sion in tissue fromMS11 .2 . As B7 was expressed in only ap-
proximately half the MS brains, we examined whether there
was a correlation between perivascular cell infiltration and
RT-PCR mRNA measurements of B7 expression . The
frequency of plaque samples with cell infiltrations of %3
correlated with positive mRNA expression of either B7-1
or B7-2 (P <0.005) .
To define the morphologic substrate ofB7 protein ex-
pression in MS plaques and cerebral vascular infarcts, sec-
tions were stained with antibodies for macrophages (EBM/
11), CD4+ T cells, B cells (CD22), and for B7-1 and B7-2 .
Representative photomicrographs are shown in Figs . 3 and
4, and the results are summarized in Table 3 . Immunocy-
tochemistry was performed on 9 control cases (2 with CNS
inflammation), 16 MS plaques, and 4 MS plaque/infarct
paired samples .
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Figure 2 . mRNA expression of IL-12p40, B7-1,
B7-2, and (3-actin in 30 CNS tissue specimens from
MS patients and normal control cases listed in Table 1 .
The samples are in a random order since the PCR
analysis was done blinded . For each PCR set an exter-
nal standard curve was generated . The concentrations
ofthe standards were 2 X 10-1 , 4 X 10-2, 8 X 10-3 ,
1.6 X 10- ', and 3.2 X 10-4 for 13-actin ; 10-z, 10-3 ,
10-4, and 10-5 for IL-12p40 ; 4 X 10-3 , 8 X 10-4, 1 .6
X 10-4 , 3.2 X 10-5, and 6 .4 X 10- s for B7-1 ; and
10 -1 , 2 X 10-2, 4 X 10-3, 8 X 10-4, and 1 .6 X 10-4
for B7-2 .
Normal control samples demonstrated characteristic mi-
croglial staining pattern with EBM/11 and occasional B
and T cells near blood vessels, but no B7-1+ or B7-2+ cells
were detected . As we observed in the PCR analysis, the
MS plaque samples with perivascular cell infiltrations of-_3
exhibited B7-1 expression that reflected staining with lym-
phocyte markers for CD2 (T cells) and CD22 (B cells) and
was restricted to the blood vessel area (Fig. 3 c and Fig . 4 a) .
This contrasted with the presence of widespread EBM/ 11 +
perivascular macrophages and parenchymal microglia. The
B7-2 staining, however, was clearly detectable on what ap-
peared to be a subpopulation of activated macrophages in
the majority of plaques, contrasting with the more re-
stricted B7-1 expression (Fig . 4) . Comparison of serially cut
sections stained with the different mAbs indicated that the
intense B7-1-stained cells were likely to be T cells, and
were detected in the inflammatory cuffs amid cells express-
ing lower levels ofB7-1 .
Based on recent experiments in the EAE model, we pos-
tulated that tissue cellular infiltrates associated with MS
would have B7-1 expression, whereas inflammation associ-
ated with tissue damage, such as that induced by stroke,
would express B7-2 . This was directly investigated bycomparing four cases with both MS and stroke associated
pathologically with inflammation. There was no B7-1 stain-
ing in the infarcts from patients with MS, whereas the asso-
ciated plaque tissue in two of four cases contained B7-l+
perivascular cells (Fig . 4, c and d, and Table 3) . On the
other hand, B7-2 expression was observed in both infarct
and plaque samples . The cerebrovascular infarct from con-
trol 10 had barely detectable staining for lymphocyte mark-
ers and B7-1 andB7-2 staining despite the presence of acti-
vated macrophages . Interestingly, the SSPE sample, which
displayed a strong PCR signal, had only a very small num-
ber of B7-1+ leukocytes, but these were intensely stained
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Figure 3 .
￿
Cryostat sections of a
perivenular inflammatory cuff and
the surrounding tissue in an in-
flammatory MS plaque from
CNSll .1 with disease duration of
1 yr . (a) Anti-CD4 ; (b) anti-CD22;
(c) anti-B7-1 ; and (d) anti-keratin
control. X98 .
and clearly detectable in a restricted number of blood ves-
sels, which was consistent with the high RT-PCR signal
found in this sample (data not shown) . As in the MS
plaques, the more widespread B7-2 staining appeared to be
associated with macrophages .
We observed an increase in expression of IL-12p40
mRNA in at least one plaque from 5 of 15 MS brains . In
cases expressing IL-12p40, the average disease duration was
6.2 ± 2.6 (SE) yr, and 4 of 5 had disease for _-8 yr,
whereas in the brains with no IL-12 expression, the average
disease duration was 19.4 ± 4.4 (SE) yr (P <0.04, two-
tailed Mann-Whitney test), and 9 of 10 cases had diseaseFigure 4 .
￿
Immunocytochemical analysis ofcryostat sections from MS plaque (a and b) and infarct tissue (c-e) from MS brain 13 .1 and 13.2. a and c are
stained with and-B7-1 (CD80) ; b and d are stained with anti-B7-2 (CD86) ; e is stained with the macrophage marker EBM 11 ; f is normal control white
matter (control 8) with anti-B7-2 staining . There was no counterstaining . B7-1 staining is localized to perivenular inflammatory cuffs inMS plaques but
not infarct areas, whereas B7-2 staining was present in both infarct andMS plaque . X370 .
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￿
Summary ofImmunohistopathology
Cell
Disease
￿
infiltra- B7-1 B7-2
dura-
￿
tion stain- stain-
Inflammatory
control tissue
Cont 9
￿
2
SSPE
￿
3 5 ++ +
Cont 10
￿
-
Infarct
￿
0 2 - -
Data are B7-1 and B7-2 staining of CNS samples, as assessed by two
observers masked for disease state and PCR data. B7-1 and B7-2 im-
munohistochemistry were graded as negative (-), positive with occa-
sional moderate staining ofperivascular cuffs (+), or maximally positive
with intensestaining ofcells in perivascular cuffs or parenchyma (++) .
Disease duration, cell infiltration on the basis ofhematoxylin and eosin
staining, and demyelination on the basis of0.7-red Ostaining is shown
forcomparison (see below forscoring methods).
*Oil-red O staining is ameasure of lipid-laden macrophages, and thus
correlates with the macrophage infiltration in the tissue and degree of
ongoing or recent demyelination. The staining is scored on a scale of
0-5 by estimating the number and density of oil-red O-positive mac-
rophages in both thearea ofperivascular cuffing and in the zone radiat-
ingto the edge ofthe normal-appearing white matter. (0 is what is ex-
petted in normal control white matter and 5 represents maximal
macrophage infiltration with oil-red O-containing material).
$Cell infiltration is scored on a scale of 0-5. Cellular infiltration as
judged by hematoxylin staining is scored on thebasis ofthe number of
inflammatory cuffs per unit field and their size and thickness, with the
range of 0-5 (0 is what is expected in normal control white matter and
5 represents maximal perivascular cellular infiltration). At least five
fields are estimated. Inflammatory lesions aredefines as perivascular cel-
lularinfiltrates >3, whereasperivascular cellular infiltrates of0-1 in MS
brain represent chronic lesions with gliosis and minimal mononuclear
cell infiltrates. In infarcts, there wasmacrophage infiltration in the tissue
with little in the wayofperivascular cuffing. Pathology was assessed by
two observers blinded as to the tissue diagnosis andPCRresults.
Continued
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for _-8 yr. There was no IL-12p40 mRNA expression in
any of the cases from control brains. As with B7 expression,
the frequency of plaque samples with cell infiltrations =3
also correlated with positive mRNA expression of IL-12
(P <0.04). To further quantitate the amounts ofIL-12p40,
we performed a competitive PCR analysis for IL-12p40.
Although less sensitive than standard PT-PCR, this tech-
nique allows amore precise quantification ofthe amount of
mRNA. IL-12p40 was detected at a concentration of2 X
10-6 attomoles/Ltl in CNS MS.11, the tissue with the
highest level of mRNA detected by semiquantitative PCR
(data not shown) . As predicted from the quantification us-
ing RT-PCR, we were unable to detect IL-12 using the
less sensitive methods of immunocytochemistry and in situ
hybridization to detect the cellular source of IL-12 mRNA.
tion
yr
Oil-red O*
macrophages
(MNC)$ ing ing
Control
CNS tissue
Case 8 0 1 - -
Case 1 0 1 - -
Case 2 0 0 - -
Case 3 0 0 - -
Case 4 0 0 - -
Case 5 0 1 - -
Case 6 0 2 - -
Case 7 0 0 - -
MS tissue
MS 1 22 1 1 - +
MS 15 15 0 5 + -
MS 4 14 0 1 - +
MS 6 10 1 2 - -
1 2 - -
MS 7 9 1 1 - ++
3 3 + ++
3 3 - ++
MS 12 8 3 4 - +
4 5 ++ ++
MS 8 7 5 3 - + +
4 2 - ++
MS 10 2 5 3 ++ ++
MS 11 1 5 5 ++ +
2 4 ++
0 2 + ND
Paired MS
plaques/infarcts
MS 2 17
Infarct 0 0 - -
Plaque 0 5 + +
0 5 + +
MS 13 50
Infarct 5 1 - ++
Plaque 1 3 + +
MS 14 16
Infarct 0 1 - -
Plaque 0 0 - -
MS 15 41
Infarct 4 2 - +
Plaque 0 1 - -
Cell
Disease infiltra- B7-1 B7-2
dura- tion stain- stain-
tion Oil-red O* (MNC)$ ing ingDiscussion
We examined the expression of the costimulatory mole-
cules B7-1 and B7-2 and IL-12p40 mRNA in the CNS of
patients with MS compared with tissue from inflammatory
infarcts, chronic viral-induced inflammatory lesions, and nor-
mal control brains. B7-1 and IL-12p40 were expressed in
acute MS plaques from early disease cases but not in the in-
flammatory infarct control tissue. B7-1 staining was local-
ized predominantly to the lymphocytes in perivenular in-
flammatory cuffs but not the parenchyma. In contrast, B7-2
was expressed predominantly on macrophages both in MS
lesions ofvaried time duration and in cerebral infarcts. These
findings suggest that an early event in the initiation of MS
involves upregulation ofB7-1 and IL-12, resulting in con-
ditions that promote T cell clonal expansion and IFN-'Y se-
cretion with the breakdown of tolerance.
Early MS lesions have predominantly perivascular lym-
phocytic cell infiltrations followed in time by the accumu-
lation of lipid-laden phagocytic macrophages that express
oil-red O staining. Patients with longer disease duration
tend to have chronic lesions with sharply demarcated gli-
otic areas, which lack inflammation. Because B7-1, B7-2,
and IL-12 were expressed in some but not all of the MS
cases, it was important to examine whether expression of
these molecules reflected either the degree of inflammation
or the disease duration. Tissue sections graded by blinded
observers with perivascular cell infiltrations %3 had signifi-
cantly higher B7-1, B7-2, or IL-12 mRNA expression.
Moreover, patients with shorter disease duration were sig-
nificantly more likely to express IL-12. In marked contrast,
other regulatory cytokines including IL-2 and IL-4 were
not observed more frequently in the inflamed MS tissue
compared with noninflammatory control brains (data not
shown).
There was not a perfect correlation between immunocy-
tochemistry and PCR analysis. In case MS 11-WM, B7-1
was expressed in the section cut for immunocytochemistry,
whereas no signal was detected in those cut for PCR, and a
high PCR signal was detected in MS 6.1, which on the ba-
Tissue Damage
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Antigen
Presenting Autoimmune Disease
Cell \
Anergized or
Th2 Type Autor eactive T cell?
IL-4
IL-10 m Regulatory
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￿
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IL-2
IM-1
TNF-a
1993
￿
Windhagen et al.
sis of immunocytochemistry and histological analysis was
not inflammatory. This may relate to technical issues such
as tissue storage with mRNA degradation or differences in
pathology from different sections of the same tissue block.
Alternatively, these differences may relate to posttranscrip-
tional regulation of B7-1 expression in the inflammatory
cells infiltrating the lesions .
Perhaps the most convincing data to suggest that B7 ex-
pression is associated with MS lesions and is not related
simply to macrophage infiltration were obtained by com-
paring B7-1 and B7-2 expression in inflammatory MS
plaques and inflammatory strokes from the same brain. This
provided a control for other factors that may be associated
with B7 or IL-12 expression in the brain, such as HLA type
or other genetic influences. There was significant inflam-
mation in the areas of infarct, as evidenced by either cell in-
filtration or oil-red O staining of macrophages. In the two
MS cases with cell infiltration, B7-1 was expressed pre-
dominantly on the lymphocytes in the MS plaques but not
in the stroke lesions. In striking contrast, B7-2 expression
was observed predominantly on macrophages both in the
MS plaques and cerebral infarcts. These data indicate that
inflammatory MS plaques but not cerebral infarcts are asso-
ciated with B7-1 expression. A low level of B7-2 expres-
sion was also found in RT-PCR in noninflammatory con-
trol brains, which may represent constitutive expression on
microglia as B7-2 is expressed on resting monocytes. Our
results of increased B7-1 expression in the MS brain are
also consistent with recently published results by Antel (51)
and Aloisi (52) .
Myelin exposure to T cells after a break in the blood-
brain barrier after stroke, trauma, or tumor does not result
in autoimmune demyelination. Our data suggest that this
may relate to the regulated absence of B7-1 expression at
the lesion. That is, autoreactive T cells stimulated at tissue
sites with B7-2 costimulation do not induce tissue destruc-
tion but instead induce scar formation with tissue fibrosis.
Thus, autoreactive T cells may function to regulate nonvi-
ral-induced tissue destruction, as may occur in the brain
Effector Cells
Cells
Figure 5. Model for the role of B7 costimulatory
molecules in the induction ofautoimmune disease. Au-
toreactive T cells stimulated at tissue sites with B7-2
costimulation do not induce tissue destruction but in-
stead lead to scar formation with tissue fibrosis. Thus,
autoreactive T cells may function to regulate nonviral-
induced tissue destruction, as may occur in the brain
with stroke. In contrast, costimulation with B7-1 in
addition to B7-2 on organ-specific APC leads to effec-
tor-autoreactive T cells. It is postulated that B7-1 ex-
pression is induced by either systemically activated T
cells inducing B7-1 by gp39-CD40 interactions on
CNS APC or by a direct CNS viral infection. Similarly,
we postulate IL-12 secretion by CNS APC is induced
by IFN-y secretion by systemically activated T cells.with stroke. In contrast, costimulation with B7-1 in addi-
tion to B7-2 on organ-specific APC leads to effector au-
toreactive T cells (Fig. 5) . Interestingly, B7-1 expression
has also been found in active skin lesions from psoriasis pa-
tients (53), suggesting that B7 might indeed be involved in
a variety of autoimmune diseases.
A critical question remains as to what might induce ex-
pression o£B7-1 and IL-12 in MS brains, and whether this
is a primary or secondary event in the disease pathogenesis.
Although data from the transgenic diabetes model would
suggest that 137 expression in a genetically predisposed indi-
vidual may trigger the disease, it may not be possible to for-
mally prove this hypothesis in human autoimmune disease.
MHC class II is constitutively expressed in the healthy brain
and was found to be upregulated in inflammatory MS le-
sions, and could therefore synergize with B7-1 (54, 55).
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